Therapy for primary and metastatic cancers
A technology of nucleic acid, seqidno., applied in immunotherapy for the treatment of metastatic tumors,
[field
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0076] Adenoviruses are usually double-stranded DNA genome viruses that cause respiratory, intestinal, and eye infections in humans or animals. The virus that causes the common cold is an adenovirus. Oncolytic viruses of the present invention include genetically engineered adenovirus Ad5 variants. The present invention employs specific genetically engineered variants of the Ad5 virus, including S98-001 (SeqID #1) or S98-002 (SeqID #2). Although not wanting to be bound by theory, it is well known that humans infected with wild-type Ad5 are self-healing. In addition, Ad5 adenovirus has been routinely used as a vector for gene therapy because there is no report that a DNA fragment of Ad5 genome can be integrated into the genome of human cells. Thus, the present invention also employs the synchronization of injection of specific oncolytic viruses and high temperature to inhibit cancer at the site of injection and away from the site of virus injection. Although oncolytic Ad5 var...
Embodiment 2
[0099] To determine effective dosage regimens for animals (including, for example, humans) treated with the compositions and methods of the invention, five dosage levels of H101 (SEQ ID #1) were used. Recombinant adenovirus was administered by intratumoral injection to patients with advanced solid tumors. One objective was to determine the maximum resistant dose ("MTD") and safety of intratumoral injection of H101 (SEQID #1). The 5 levels of H101 (SEQID #1) used are shown in Table 2 and the dose escalation curves are shown in Figure 3. Three patients were included for each of the five independent dose levels. The MTD was determined from the dose at which 2 patients experienced DLTs including influenza-like grade 4 toxicity due to H101 (SEQ ID #1), grade 4 toxicity due to local reactions at the injection site of H101 (SEQ ID #1), or due to Any other grade 3 toxicity from H101 (SEQID #1). If one of the three patients develops a DLT, that group will treat a total of six patien...
Embodiment 3
[0105] Treatment of cancer patients with oncolytic virus S98-001 (SEQID#1) synchronized with hyperthermia. The patient's date of birth was June 10, 1943. In 1990, he was diagnosed with nasopharyngeal carcinoma. After a period of treatment with radiotherapy, the development of the primary tumor is clinically controlled. However, two tumors in the right cervical and supraclavicular regions slowly developed during these years. At the end of 2001, the two tumors were treated by radiotherapy (cobalt-60, DT 34 Gy / 17F / 24d) combined with hyperthermia. Unfortunately, these treatments did not inhibit the progression of both tumors. The patient was hospitalized in early February 2002, and a physical examination was performed on the patient prior to treatment with oncolytic virus S98-001 (SEQID#1) synchronized with hyperthermia. The patient's general physical condition was good, but his nasopharyngeal tissue was nodularly thickened and slightly congested. The surfaces of both tumors ...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com